BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines capital Expenditures Incurred but Not Yet Paid ($M) ($M)
Form 10-Q / 10-K Supplemental Cash Flow Information (XBRL)
Latest, Q2 2026
5.90
Period ended Jun 30, 2026
Change on a year earlier
-381.0%
-2.10 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
34
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Capital Expenditures Incurred but Not Yet Paid ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 5.90 | -381.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 43.2 | -28.0% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 5.20 | -204.0% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | -5.90 | -85.3% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | -2.10 | -113.9% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 60 | -40.3% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | -5 | -68.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | -40.2 | -429.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 15.1 | -51.9% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 101 | +57.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | -15.8 | -132.9% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 12.2 | -207.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 31.4 | -865.9% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 64 | +2.1% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 48 | +324.8% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | -11.4 | -187.7% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | -4.10 | +105.0% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 62.7 | +102.9% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 11.3 | -4.2% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 13 | +550.0% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | -2 | -180.0% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 30.9 | +17.0% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 11.8 | -6,000.0% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 2 | -129.9% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 2.50 | -28.6% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 26.4 | -18.8% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | -0.20 | -102.0% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | -6.70 | -267.5% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 3.50 | -20.5% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 32.5 | +802.8% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 10.1 | +1,342.9% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 4 | +3,900.0% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 4.40 | -650.0% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 3.60 | +63.6% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 0.70 | -61.1% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2017 | Sep 30, 2017 | 0.10 | -50.0% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2017 | Jun 30, 2017 | -0.80 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 2.20 | +2,100.0% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 1.80 | -1,900.0% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2016 | Sep 30, 2016 | 0.20 | +100.0% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | -0 | -100.0% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 0.10 | 0.0% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | -0.10 | – | Form 10-K (filed 2018-02-28) ↗ |
| Q3 2015 | Sep 30, 2015 | 0.10 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | -0.10 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 0.10 | – | 10-Q FY2015 (XBRL) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Capital Expenditures Incurred but Not Yet Paid ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/capex_unpaid
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.